These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 18632556)
1. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. White MD; Farmer M; Mirabile I; Brandner S; Collinge J; Mallucci GR Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10238-43. PubMed ID: 18632556 [TBL] [Abstract][Full Text] [Related]
2. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. Pfeifer A; Eigenbrod S; Al-Khadra S; Hofmann A; Mitteregger G; Moser M; Bertsch U; Kretzschmar H J Clin Invest; 2006 Dec; 116(12):3204-10. PubMed ID: 17143329 [TBL] [Abstract][Full Text] [Related]
3. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations. Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523 [TBL] [Abstract][Full Text] [Related]
4. Therapy for prion diseases: Insights from the use of RNA interference. White MD; Mallucci GR Prion; 2009; 3(3):121-8. PubMed ID: 19597349 [TBL] [Abstract][Full Text] [Related]
6. RNAi: a novel strategy for the treatment of prion diseases. Kong Q J Clin Invest; 2006 Dec; 116(12):3101-3. PubMed ID: 17143323 [TBL] [Abstract][Full Text] [Related]
7. Pathogenic mutations within the hydrophobic domain of the prion protein lead to the formation of protease-sensitive prion species with increased lethality. Coleman BM; Harrison CF; Guo B; Masters CL; Barnham KJ; Lawson VA; Hill AF J Virol; 2014 Mar; 88(5):2690-703. PubMed ID: 24352465 [TBL] [Abstract][Full Text] [Related]
8. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease. Meier P; Genoud N; Prinz M; Maissen M; Rülicke T; Zurbriggen A; Raeber AJ; Aguzzi A Cell; 2003 Apr; 113(1):49-60. PubMed ID: 12679034 [TBL] [Abstract][Full Text] [Related]
9. Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Mallucci GR; White MD; Farmer M; Dickinson A; Khatun H; Powell AD; Brandner S; Jefferys JG; Collinge J Neuron; 2007 Feb; 53(3):325-35. PubMed ID: 17270731 [TBL] [Abstract][Full Text] [Related]
10. Gene and cell therapy for prion diseases. Relaño-Ginés A; Gabelle A; Lehmann S; Milhavet O; Crozet C Infect Disord Drug Targets; 2009 Feb; 9(1):58-68. PubMed ID: 19200016 [TBL] [Abstract][Full Text] [Related]
11. Allelic Interference in Prion Replication Is Modulated by the Convertibility of the Interfering PrP Espinosa JC; Andreoletti O; Marín-Moreno A; Lugan S; Aguilar-Calvo P; Cassard H; Lorenzo P; Douet JY; Villa-Díaz A; Aron N; Prieto I; Huor A; Torres JM mBio; 2021 Mar; 12(2):. PubMed ID: 33727358 [TBL] [Abstract][Full Text] [Related]
12. RNAi for the treatment of prion disease: a window for intervention in neurodegeneration? White MD; Mallucci GR CNS Neurol Disord Drug Targets; 2009 Nov; 8(5):342-52. PubMed ID: 19702576 [TBL] [Abstract][Full Text] [Related]
13. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Telling GC; Scott M; Mastrianni J; Gabizon R; Torchia M; Cohen FE; DeArmond SJ; Prusiner SB Cell; 1995 Oct; 83(1):79-90. PubMed ID: 7553876 [TBL] [Abstract][Full Text] [Related]
14. Mouse prion protein (PrP) segment 100 to 104 regulates conversion of PrP(C) to PrP(Sc) in prion-infected neuroblastoma cells. Hara H; Okemoto-Nakamura Y; Shinkai-Ouchi F; Hanada K; Yamakawa Y; Hagiwara K J Virol; 2012 May; 86(10):5626-36. PubMed ID: 22398286 [TBL] [Abstract][Full Text] [Related]
15. Strain-Dependent Prion Infection in Mice Expressing Prion Protein with Deletion of Central Residues 91-106. Uchiyama K; Miyata H; Yamaguchi Y; Imamura M; Okazaki M; Pasiana AD; Chida J; Hara H; Atarashi R; Watanabe H; Kondoh G; Sakaguchi S Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019549 [TBL] [Abstract][Full Text] [Related]
16. Development of antibody fragments for immunotherapy of prion diseases. Campana V; Zentilin L; Mirabile I; Kranjc A; Casanova P; Giacca M; Prusiner SB; Legname G; Zurzolo C Biochem J; 2009 Mar; 418(3):507-15. PubMed ID: 19000036 [TBL] [Abstract][Full Text] [Related]